Role for Neurokinin-2 Receptor in Interleukin-5-induced Airway Hyperresponsiveness but not Eosinophilia in Guinea Pigs
In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma. IL-5 seems to be a critical cytokine since it selectively affects eosinophil functions. The mechanism of action by which IL-5 leads to airway h...
Saved in:
Published in | American journal of respiratory and critical care medicine Vol. 156; no. 2; pp. 367 - 374 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
American Lung Association
01.08.1997
|
Subjects | |
Online Access | Get full text |
ISSN | 1073-449X 1535-4970 |
DOI | 10.1164/ajrccm.156.2.9608101 |
Cover
Loading…
Abstract | In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma. IL-5 seems to be a critical cytokine since it selectively affects eosinophil functions. The mechanism of action by which IL-5 leads to airway hyperresponsiveness may be important for our understanding of the pathogenesis of asthma. Neurogenic inflammation, which is mediated by nonadrenergic noncholinergic nerves (NANC), may play a role in the IL-5-induced effects in guinea pig airways. In this study, the role of neuropeptides in the IL-5-induced airway hyperresponsiveness and eosinophilia in the guinea pig was examined using selective neurokinin receptor antagonists. Intra-airway application of IL-5 (1 microgram, twice) induces a selective eosinophil migration (control: 12 [8-22] x 10(5) cells and IL-5: 90 [67-187] x 10(5) cells, p < 0.05) and activation (control: 6.3 +/- 0.9 ng eosinophil peroxidase [EPO]/ml bronchoalveolar lavage [BAL] fluid and IL-5: 29.3 +/- 4.9 ng EPO/ml BAL fluid, p < 0.05) and a pronounced airway hyperresponsiveness in vivo. The maximal responses to histamine are increased by 160 +/- 16% (p < 0.05) after IL-5. Treatment of guinea pigs with either the nonselective neurokinin (NK)-receptor antagonist, FK224, or the selective NK2-receptor antagonist, SR48968, results in a complete inhibition of the in vivo hyperresponsiveness found after application of IL-5. Vice versa, intra-airway administration of substance P (10 micrograms, twice) results in an airway hyperresponsiveness (increased maximal response after substance P: 166 +/- 15% [p < 0.05]) without inducing migration or activation of eosinophils. All examined NK-receptor antagonists do not influence the IL-5-induced eosinophil accumulation. In addition, no effect of the NK-receptor antagonists is observed on the IL-5-induced eosinophil activation, as determined by BAL fluid EPO levels. The release of NK2-receptor active tachykinins plays an important role in the development of IL-5-induced airway hyperresponsiveness. This feature appears to be a step following eosinophil infiltration and activation since there are no effects on eosinophil function by pretreatment of the used NK-receptor antagonists. |
---|---|
AbstractList | In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma. IL-5 seems to be a critical cytokine since it selectively affects eosinophil functions. The mechanism of action by which IL-5 leads to airway hyperresponsiveness may be important for our understanding of the pathogenesis of asthma. Neurogenic inflammation, which is mediated by nonadrenergic noncholinergic nerves (NANC), may play a role in the IL-5-induced effects in guinea pig airways. In this study, the role of neuropeptides in the IL-5-induced airway hyperresponsiveness and eosinophilia in the guinea pig was examined using selective neurokinin receptor antagonists. Intra-airway application of IL-5 (1 microgram, twice) induces a selective eosinophil migration (control: 12 [8-22] x 10(5) cells and IL-5: 90 [67-187] x 10(5) cells, p < 0.05) and activation (control: 6.3 +/- 0.9 ng eosinophil peroxidase [EPO]/ml bronchoalveolar lavage [BAL] fluid and IL-5: 29.3 +/- 4.9 ng EPO/ml BAL fluid, p < 0.05) and a pronounced airway hyperresponsiveness in vivo. The maximal responses to histamine are increased by 160 +/- 16% (p < 0.05) after IL-5. Treatment of guinea pigs with either the nonselective neurokinin (NK)-receptor antagonist, FK224, or the selective NK2-receptor antagonist, SR48968, results in a complete inhibition of the in vivo hyperresponsiveness found after application of IL-5. Vice versa, intra-airway administration of substance P (10 micrograms, twice) results in an airway hyperresponsiveness (increased maximal response after substance P: 166 +/- 15% [p < 0.05]) without inducing migration or activation of eosinophils. All examined NK-receptor antagonists do not influence the IL-5-induced eosinophil accumulation. In addition, no effect of the NK-receptor antagonists is observed on the IL-5-induced eosinophil activation, as determined by BAL fluid EPO levels. The release of NK2-receptor active tachykinins plays an important role in the development of IL-5-induced airway hyperresponsiveness. This feature appears to be a step following eosinophil infiltration and activation since there are no effects on eosinophil function by pretreatment of the used NK-receptor antagonists.In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma. IL-5 seems to be a critical cytokine since it selectively affects eosinophil functions. The mechanism of action by which IL-5 leads to airway hyperresponsiveness may be important for our understanding of the pathogenesis of asthma. Neurogenic inflammation, which is mediated by nonadrenergic noncholinergic nerves (NANC), may play a role in the IL-5-induced effects in guinea pig airways. In this study, the role of neuropeptides in the IL-5-induced airway hyperresponsiveness and eosinophilia in the guinea pig was examined using selective neurokinin receptor antagonists. Intra-airway application of IL-5 (1 microgram, twice) induces a selective eosinophil migration (control: 12 [8-22] x 10(5) cells and IL-5: 90 [67-187] x 10(5) cells, p < 0.05) and activation (control: 6.3 +/- 0.9 ng eosinophil peroxidase [EPO]/ml bronchoalveolar lavage [BAL] fluid and IL-5: 29.3 +/- 4.9 ng EPO/ml BAL fluid, p < 0.05) and a pronounced airway hyperresponsiveness in vivo. The maximal responses to histamine are increased by 160 +/- 16% (p < 0.05) after IL-5. Treatment of guinea pigs with either the nonselective neurokinin (NK)-receptor antagonist, FK224, or the selective NK2-receptor antagonist, SR48968, results in a complete inhibition of the in vivo hyperresponsiveness found after application of IL-5. Vice versa, intra-airway administration of substance P (10 micrograms, twice) results in an airway hyperresponsiveness (increased maximal response after substance P: 166 +/- 15% [p < 0.05]) without inducing migration or activation of eosinophils. All examined NK-receptor antagonists do not influence the IL-5-induced eosinophil accumulation. In addition, no effect of the NK-receptor antagonists is observed on the IL-5-induced eosinophil activation, as determined by BAL fluid EPO levels. The release of NK2-receptor active tachykinins plays an important role in the development of IL-5-induced airway hyperresponsiveness. This feature appears to be a step following eosinophil infiltration and activation since there are no effects on eosinophil function by pretreatment of the used NK-receptor antagonists. In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma. IL-5 seems to be a critical cytokine since it selectively affects eosinophil functions. The mechanism of action by which IL-5 leads to airway hyperresponsiveness may be important for our understanding of the pathogenesis of asthma. Neurogenic inflammation, which is mediated by nonadrenergic noncholinergic nerves (NANC), may play a role in the IL-5-induced effects in guinea pig airways. In this study, the role of neuropeptides in the IL-5-induced airway hyperresponsiveness and eosinophilia in the guinea pig was examined using selective neurokinin receptor antagonists. Intra-airway application of IL-5 (1 microgram, twice) induces a selective eosinophil migration (control: 12 [8-22] x 10(5) cells and IL-5: 90 [67-187] x 10(5) cells, p < 0.05) and activation (control: 6.3 +/- 0.9 ng eosinophil peroxidase [EPO]/ml bronchoalveolar lavage [BAL] fluid and IL-5: 29.3 +/- 4.9 ng EPO/ml BAL fluid, p < 0.05) and a pronounced airway hyperresponsiveness in vivo. The maximal responses to histamine are increased by 160 +/- 16% (p < 0.05) after IL-5. Treatment of guinea pigs with either the nonselective neurokinin (NK)-receptor antagonist, FK224, or the selective NK2-receptor antagonist, SR48968, results in a complete inhibition of the in vivo hyperresponsiveness found after application of IL-5. Vice versa, intra-airway administration of substance P (10 micrograms, twice) results in an airway hyperresponsiveness (increased maximal response after substance P: 166 +/- 15% [p < 0.05]) without inducing migration or activation of eosinophils. All examined NK-receptor antagonists do not influence the IL-5-induced eosinophil accumulation. In addition, no effect of the NK-receptor antagonists is observed on the IL-5-induced eosinophil activation, as determined by BAL fluid EPO levels. The release of NK2-receptor active tachykinins plays an important role in the development of IL-5-induced airway hyperresponsiveness. This feature appears to be a step following eosinophil infiltration and activation since there are no effects on eosinophil function by pretreatment of the used NK-receptor antagonists. |
Author | KRANEVELD, ALETTA D. NIJKAMP, FRANS P. VAN OOSTERHOUT, ANTOON J. M. |
Author_xml | – sequence: 1 givenname: ALETTA D. surname: KRANEVELD fullname: KRANEVELD, ALETTA D. organization: Department of Pharmacology and Pathophysiology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands – sequence: 2 givenname: FRANS P. surname: NIJKAMP fullname: NIJKAMP, FRANS P. organization: Department of Pharmacology and Pathophysiology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands – sequence: 3 givenname: ANTOON J. M. surname: VAN OOSTERHOUT fullname: VAN OOSTERHOUT, ANTOON J. M. organization: Department of Pharmacology and Pathophysiology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2785401$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9279211$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUFv1DAQhS1UVNrCPwDJB8Qti8dxnJhbVZW2UgWoAomb5TgTcMnawXaK9t_j1UY99NDTjOZ9b0aad0qOfPBIyFtgGwApPpr7aO12A43c8I2SrAMGL8gJNHVTCdWyo9Kztq6EUD9fkdOU7hkDXqhjcqx4qzjACXm4CxPSMUT6BZcY_jjvfMXpHVqcc5k6T298xjjhUrSqqZwfFosDPXfxn9nR692MMWKag0_uAT2mRPslUx8yvQzJ-TD_dpMz-0VXi_No6Df3K70mL0czJXyz1jPy4_Pl94vr6vbr1c3F-W1l6xpy1Q014IC1kYzbWlrJjbJ90yqwIKHtxSCRWzl0XBjedqMyXIKQthc9tl0j6jPy4bB3juHvginrrUsWp8l4DEvS5QtCtp0q4LsVXPotDnqObmviTq-PKvr7VTfJmmmMxluXHjG-v8b2mDhgNoaUIo6PBDC9T00fUtMlNc31mlqxfXpisy6b7ILP0bjpefN_iwygLQ |
CitedBy_id | crossref_primary_10_3390_ani11051376 crossref_primary_10_1152_ajplung_00179_2022 crossref_primary_10_1038_sj_bjp_0704310 crossref_primary_10_1016_S0014_2999_00_00546_X crossref_primary_10_1002_bab_2533 crossref_primary_10_1146_annurev_immunol_17_1_255 crossref_primary_10_1034_j_1398_9995_2000_00112_x crossref_primary_10_1152_ajpregu_00001_2002 crossref_primary_10_1046_j_1365_2222_2002_01328_x crossref_primary_10_1016_j_ejphar_2005_12_066 crossref_primary_10_1046_j_1365_2222_1999_00683_x crossref_primary_10_1084_jem_187_6_939 crossref_primary_10_1111_j_1365_2222_2006_02547_x crossref_primary_10_1517_13543776_17_10_1241 crossref_primary_10_1111_j_1365_2222_2006_02549_x crossref_primary_10_1164_ajrccm_161_6_9905039 crossref_primary_10_1016_j_crimmu_2021_06_001 crossref_primary_10_1016_j_resp_2007_08_004 crossref_primary_10_1517_13543776_11_7_1097 crossref_primary_10_1016_S0014_2999_01_01138_4 crossref_primary_10_1080_02770900701496080 crossref_primary_10_1016_S0014_2999_01_01323_1 crossref_primary_10_1016_S1567_5769_01_00099_6 crossref_primary_10_1164_ajrccm_159_5_9808058 crossref_primary_10_1016_S0014_2999_02_01365_1 crossref_primary_10_1016_S0192_0561_97_00085_4 crossref_primary_10_1067_mai_2000_106636 crossref_primary_10_1016_S1471_4892_01_00042_X crossref_primary_10_1111_j_1365_2222_2008_03097_x crossref_primary_10_1164_ajrccm_162_3_9910089 crossref_primary_10_1016_j_ejphar_2013_10_029 crossref_primary_10_1378_chest_123_2_524 crossref_primary_10_1038_sj_bjp_0705515 |
Cites_doi | 10.1164/ajrccm.149.2.8306037 10.1172/JCI115166 10.1159/000235396 10.1164/ajrccm/148.4_Pt_1.927 10.1164/ajrccm.151.6.7767518 10.1164/ajrccm/148.6_Pt_1.1623 10.1111/j.1476-5381.1995.tb13220.x 10.1016/S0091-6749(95)70039-0 10.1016/0014-2999(93)90831-2 10.1183/09031936.96.09030493 10.1152/ajplegacy.1958.192.2.364 10.1183/09031936.93.04060673 10.1111/j.1476-5381.1992.tb14394.x 10.1016/0091-6749(93)90118-Y 10.1164/ajrccm/143.3.572 10.1164/ajrccm/144.5.1187 10.1164/ajrccm/148.4_Pt_1.915 10.3109/01902149109064334 10.1016/0014-2999(87)90244-5 10.1002/eji.1830190420 10.1165/ajrcmb.12.3.7873198 10.1164/ajrccm/147.4.982 10.1016/0022-1759(85)90242-X 10.1165/ajrcmb/7.6.631 10.1164/ajrccm.151.2.7531100 10.1006/pulp.1994.1020 10.1164/ajrccm/147.3.548 10.1164/ajrccm.153.1.8542107 10.1152/jappl.1994.77.3.1325 10.1016/0091-6749(92)90138-R 10.1182/blood.V73.6.1504.1504 10.1111/j.1432-1033.1993.tb17714.x 10.4049/jimmunol.145.8.2581 10.1136/thx.42.10.779 10.1172/JCI117594 10.1016/0143-4179(93)90048-F 10.1016/0091-6749(93)90085-T 10.1111/j.1365-2222.1993.tb02481.x 10.1016/0014-2999(93)90475-W 10.1164/ajrccm/146.1.148 10.1164/ajrccm/143.3.533 10.1182/blood.V79.12.3101.bloodjournal79123101 10.1164/ajrccm/144.2.368 10.1111/j.1476-5381.1995.tb15917.x 10.1155/S0962935194000098 10.1016/0091-6749(88)90230-8 10.1111/j.1476-5381.1993.tb13867.x 10.1111/j.1476-5381.1993.tb12888.x |
ContentType | Journal Article |
Copyright | 1997 INIST-CNRS |
Copyright_xml | – notice: 1997 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1164/ajrccm.156.2.9608101 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1535-4970 |
EndPage | 374 |
ExternalDocumentID | 9279211 2785401 10_1164_ajrccm_156_2_9608101 |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GroupedDBID | --- -~X .55 .GJ 0R~ 1KJ 23M 2WC 3O- 53G 5GY 5RE 7RV 7X7 8C1 AAWTL AAYXX ABJNI ABOCM ABPMR ACBNA ACGFO ACGFS ADBBV AENEX AFCHL AFFNX AHMBA AI. ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BENPR C45 CITATION CS3 DIK E3Z EBS EJD EX3 F5P FRP GX1 H13 HZ~ IH2 J5H KQ8 L7B M5~ N4W O9- OBH OFXIZ OGEVE OK1 OVD OVIDX P2P SJN TEORI THO TR2 VH1 W8F WH7 WOQ WOW X7M ZGI ZXP ~02 1CY 34G 39C 88E 8AO 8FI 8FJ 8FW 8R4 8R5 AAEJM AAQQT ABUWG AFKRA AFUWQ AJJEV AN0 BKEYQ BNQBC BPHCQ BVXVI CCPQU EMOBN FYUFA HMCUK IQODW M1P NAPCQ OHT PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q2X RWL TAE UKHRP YJK ZE2 3V. ACRZS CGR CUY CVF ECM EIF NPM RPM VXZ YCJ 7X8 |
ID | FETCH-LOGICAL-c331t-8d31ede3a602c36c62a9cb5791c1617b4d6e2c6d824a278f9a26146cb4be78543 |
ISSN | 1073-449X |
IngestDate | Thu Jul 10 17:50:57 EDT 2025 Wed Feb 19 01:13:04 EST 2025 Mon Jul 21 09:16:50 EDT 2025 Tue Jul 01 00:53:43 EDT 2025 Thu Apr 24 23:09:44 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Immunopathology Allergy Neurokinin 2 Hyperreactivity Respiratory disease Pathogenesis Cytokine Hemopathy Eosinophilia Asthma Pig Respiratory tract Vertebrata Mammalia Interleukin 5 Animal Artiodactyla Obstructive pulmonary disease Ungulata |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c331t-8d31ede3a602c36c62a9cb5791c1617b4d6e2c6d824a278f9a26146cb4be78543 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 9279211 |
PQID | 79246789 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_79246789 pubmed_primary_9279211 pascalfrancis_primary_2785401 crossref_primary_10_1164_ajrccm_156_2_9608101 crossref_citationtrail_10_1164_ajrccm_156_2_9608101 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 1997-08-01 |
PublicationDateYYYYMMDD | 1997-08-01 |
PublicationDate_xml | – month: 08 year: 1997 text: 1997-08-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | American journal of respiratory and critical care medicine |
PublicationTitleAlternate | Am J Respir Crit Care Med |
PublicationYear | 1997 |
Publisher | American Lung Association |
Publisher_xml | – name: American Lung Association |
References | B20 Garland A. (B45) 1993; 147 B21 B22 B23 B24 B25 Bai T. R. (B43) 1995; 269 B26 B27 B28 B29 Fischer A. (B38) 1994; 149 B30 B32 B33 B34 B35 B36 B37 B39 B1 B2 B3 B4 B5 B6 B7 B8 B9 Ollerenshaw S. L. (B31) 1991; 4 B40 B41 B42 B46 B47 B48 B49 Kraneveld A. D. (B14) 1996; 153 B50 B51 B10 B11 B12 B13 B15 B16 B17 B18 B19 Kroegel C. (B44) 1990; 145 |
References_xml | – ident: B49 doi: 10.1164/ajrccm.149.2.8306037 – ident: B3 doi: 10.1172/JCI115166 – ident: B33 doi: 10.1159/000235396 – ident: B51 doi: 10.1164/ajrccm/148.4_Pt_1.927 – ident: B50 doi: 10.1164/ajrccm.151.6.7767518 – ident: B5 doi: 10.1164/ajrccm/148.6_Pt_1.1623 – ident: B21 doi: 10.1111/j.1476-5381.1995.tb13220.x – ident: B12 doi: 10.1016/S0091-6749(95)70039-0 – ident: B20 doi: 10.1016/0014-2999(93)90831-2 – ident: B13 doi: 10.1183/09031936.96.09030493 – ident: B24 doi: 10.1152/ajplegacy.1958.192.2.364 – volume: 4 start-page: 673 year: 1991 ident: B31 publication-title: Eur. Respir. J. doi: 10.1183/09031936.93.04060673 – ident: B27 doi: 10.1111/j.1476-5381.1992.tb14394.x – ident: B28 doi: 10.1016/0091-6749(93)90118-Y – ident: B36 doi: 10.1164/ajrccm/143.3.572 – ident: B15 doi: 10.1164/ajrccm/144.5.1187 – ident: B39 doi: 10.1164/ajrccm/148.4_Pt_1.915 – ident: B37 doi: 10.3109/01902149109064334 – ident: B40 doi: 10.1016/0014-2999(87)90244-5 – ident: B8 doi: 10.1002/eji.1830190420 – ident: B48 doi: 10.1165/ajrcmb.12.3.7873198 – ident: B47 doi: 10.1164/ajrccm/147.4.982 – ident: B25 doi: 10.1016/0022-1759(85)90242-X – ident: B10 doi: 10.1165/ajrcmb/7.6.631 – ident: B34 doi: 10.1164/ajrccm.151.2.7531100 – ident: B42 doi: 10.1006/pulp.1994.1020 – ident: B4 doi: 10.1164/ajrccm/147.3.548 – volume: 153 start-page: A141 year: 1996 ident: B14 publication-title: Am. J. Respir. Crit. Care Med. doi: 10.1164/ajrccm.153.1.8542107 – ident: B35 doi: 10.1152/jappl.1994.77.3.1325 – ident: B32 doi: 10.1016/0091-6749(92)90138-R – ident: B6 doi: 10.1182/blood.V73.6.1504.1504 – volume: 147 start-page: A816 year: 1993 ident: B45 publication-title: Am. Rev. Respir. Dis. – ident: B26 doi: 10.1111/j.1432-1033.1993.tb17714.x – volume: 145 start-page: 2581 year: 1990 ident: B44 publication-title: J. Immunol. doi: 10.4049/jimmunol.145.8.2581 – ident: B41 doi: 10.1136/thx.42.10.779 – ident: B46 doi: 10.1172/JCI117594 – ident: B18 doi: 10.1016/0143-4179(93)90048-F – volume: 269 start-page: L309 year: 1995 ident: B43 publication-title: Am. J. Physiol. – ident: B29 doi: 10.1016/0091-6749(93)90085-T – ident: B30 doi: 10.1111/j.1365-2222.1993.tb02481.x – ident: B11 doi: 10.1016/0014-2999(93)90475-W – ident: B16 doi: 10.1164/ajrccm/146.1.148 – ident: B2 doi: 10.1164/ajrccm/143.3.533 – ident: B7 doi: 10.1182/blood.V79.12.3101.bloodjournal79123101 – ident: B19 doi: 10.1164/ajrccm/144.2.368 – ident: B17 doi: 10.1111/j.1476-5381.1995.tb15917.x – volume: 149 start-page: A890 year: 1994 ident: B38 publication-title: Am. J. Respir. Crit. Care Med. – ident: B9 doi: 10.1155/S0962935194000098 – ident: B1 doi: 10.1016/0091-6749(88)90230-8 – ident: B22 doi: 10.1111/j.1476-5381.1993.tb13867.x – ident: B23 doi: 10.1111/j.1476-5381.1993.tb12888.x |
SSID | ssj0012810 |
Score | 1.7149007 |
Snippet | In the guinea pig, interleukin-5 (IL-5) has been shown to induce airway hyperresponsiveness as well as eosinophilia, which are important symptoms in asthma.... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 367 |
SubjectTerms | Airway Resistance - drug effects Animals Biological and medical sciences Bronchial Hyperreactivity - chemically induced Bronchial Hyperreactivity - physiopathology Bronchoalveolar Lavage Fluid - cytology Chronic obstructive pulmonary disease, asthma Dipeptides - pharmacology Eosinophilia - chemically induced Eosinophilia - physiopathology Eosinophils - cytology Eosinophils - drug effects Eosinophils - physiology Guinea Pigs Indoles - pharmacology Interleukin-5 - pharmacology Leukocyte Count - drug effects Male Medical sciences Peptides, Cyclic - pharmacology Pneumology Receptors, Neurokinin-2 - antagonists & inhibitors Receptors, Neurokinin-2 - drug effects Receptors, Neurokinin-2 - physiology Specific Pathogen-Free Organisms Substance P - pharmacology |
Title | Role for Neurokinin-2 Receptor in Interleukin-5-induced Airway Hyperresponsiveness but not Eosinophilia in Guinea Pigs |
URI | https://www.ncbi.nlm.nih.gov/pubmed/9279211 https://www.proquest.com/docview/79246789 |
Volume | 156 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLaqISEkhLhNFBj4gbfIYbEdN3msGKhrtRaNDu0tchwHCiOt2gQEv40fx7HjpNkoGvASVWntRP6-Hp_jc0PoRRYLHskgJ1xmjPD4MCSRChSJc1AWtIYtT9lqn1MxOuPj8_C81_vZiVqqytRXP3bmlfwPqnAPcDVZsv-AbDsp3IDPgC9cAWG4_hXGpyY00MQJ2qqUn02vB0I9kGF6Vdo4c1sNYn2hK_iOhATs78r4--Vi_U1-9z6CDWp6c9ggWSf00qr0imXp6eVmUSxX5rhFmok-VKCOSm-1cOfqTeHaxuHTqUCx7njvbdZc003BRplddeZPTodT0wj0yEopfxuBPD0eT4Ynb6127W_T0N4Pp95s9g608NHsbO4GjX13qpu5hL5BGz1XdlIGTIviyh0DdTlZC2UQQ4Rz23J3K7XreuSOnrQjg1nd38Nt56xuAvT7TiG42QY_rZX64sNkPvXBmDPlzrY7YxMNcGXDbMMY6SAChRds7xsUjBTTP-PoeNL6sGjkamG4t3eJm_Dgl7see0kxur2SGwAmr5ur_Nn6sVrQ_C6648wXPKy5eA_1dHEf3TxxmD5AXw0lMVASdymJG0riRYF3UhLXlMQ7KImBkhgoibuUNBPVlMSGkg_R2ZvX81cj4lp7EMVYUJIoY4HONJPikComlKAyVmk4iANlDO6UZ0JTJbKIcgmrnMcSLH0uVMpTbRad7aO9YlnoRwiHlEkl5YAplXPNRZplucpSnYFlI3nI-4g165ooV_fetF-5SKz9K3hSo5EAGglNHBp9RNpRq7ruyzW_P7gEWTvIcaSPnjcQJiDAjVdOFnpZbZJBTEFZieI-2q-RbYfGprhnEDy-Zuon6Nb2f_UU7ZXrSh-AplymzywhfwESUsOk |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+for+neurokinin-2+receptor+in+interleukin-5-induced+airway+hyperresponsiveness+but+not+eosinophilia+in+guinea+pigs&rft.jtitle=American+journal+of+respiratory+and+critical+care+medicine&rft.au=KRANEVELD%2C+A.+D&rft.au=NIJKAMP%2C+F.+P&rft.au=VAN+OOSTERHOUT%2C+A.+J.+M&rft.date=1997-08-01&rft.pub=American+Lung+Association&rft.issn=1073-449X&rft.volume=156&rft.issue=2&rft.spage=367&rft.epage=374&rft_id=info:doi/10.1164%2Fajrccm.156.2.9608101&rft.externalDBID=n%2Fa&rft.externalDocID=2785401 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1073-449X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1073-449X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1073-449X&client=summon |